NuCana PLC at Cowen Health Care Conference Transcript
Good morning, everyone. My name is Hangfei Fu, part of the TD Cowen equity research team. We're continuing the 43rd TD Cowen Healthcare Conference today with NuCana, joined by the company's Founder and CEO, Hugh Griffith. He's going to give us a presentation on the business and we'll have a short Q&A. With that, let me pass it over to Hugh.
Good morning, and a huge thank you to the Cowen team for this invitation today to present. So the name NuCana represents new cancer agents and particularly nucleotide analogs.
I will be making some forward-looking statements throughout the course of this presentation, so I'd like to refer you to this disclaimer slide, please.
So what are we doing in NuCana? Well, we're harnessing the power of phosphoramidate chemistry, and in so doing so, we're creating these compounds that we call ProTides. And we genuinely believe that they represent a new era in oncology.
So traditionally, the pharmaceutical
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |